May 19, 2026 ScienceUncovering repurposed medicines to fight liver fibrosis ShareLiver fibrosis is a scarring process that can lead to cirrhosis, which causes more than 1.4 million deaths each year. Geneticist Gary Peltz at Stanford University School of Medicine is using Co-Scientist to accelerate the hunt for medicines that can slow, stop, or reverse it.In research published in Advanced Science, Peltz’s team explored whether Co-Scientist could support efforts to identify drugs from the vast literature of existing medicines that could be repurposed to treat fibrosis. Peltz asked Co-Scientist to propose three candidates and explain its reasoning. He also identified two candidate drugs himself, based on their notable presence in the liver fibrosis literature.Then Peltz put all five drugs through his lab’s fibrosis testbed, which consists of live human liver cells. His two drug picks showed no benefit against fibrosis. By contrast, of the three drug candidates selected by Co-Scientist, two blocked fibrosis and promoted the regeneration of liver cells. One of these drugs had only been linked to liver fibrosis in a handful of papers – a needle in the haystack of scientific literature.Co-Scientist’s standout pick was the cancer drug vorinostat. In Peltz’s experiments, it blocked 91% of a damage response that can drive liver scarring. Co-Scientist’s suggestions pointed toward drugs that reshape gene activity, rather than targeting a single fibrosis pathway. Peltz argues that such drugs deserve serious consideration as treatments for liver fibrosis, and could ultimately help launch a new generation of anti-fibrotic medicines.Co-Scientist feels like a collaborator that’s read everything available about biomedical science, with the reasoning capabilities to find the connections that we’re currently missing. Professor Gary Peltz Stanford University School of Medicine Related postsCo-Scientist: A multi-agent AI partner to accelerate researchMay 2026Science Learn more Uniting biological toolkits for a new approach to ALSMay 2026Science Learn more Accelerating discovery of liver disease mechanismsMay 2026Science Learn more Opening new paths in aging researchMay 2026Science Learn more Finding the molecular switches behind new infectious diseasesMay 2026Science Learn more Fast-tracking genetic leads to reverse cellular agingMay 2026Science Learn more
Co-Scientist
Finding new treatments for liver fibrosis
Related
ResearchLearning When to Trust via Selective Context Preference Optimization
Language models increasingly condition their answers on external signals, and a single misleading one can turn a correct answer wrong. The obvious remedy, training models to resist such signals, hides a failure mode: a model that ignores all context looks robust yet is useless when the context is worth trusting. We recast the problem as selective trust and introduce MIST, a human-annotated benchmark that renders each reasoning item under four matched conditions (clean, misleading, correct-context, and irrelevant-context), together with SC2W, a paired metric counting how often a misle
Learning When to Trust via Selective Context Preference Optimization
Language models increasingly condition their answers on external signals, and a single misleading one can turn a correct answer wrong. The obvious remedy, tr...
ResearchTracing the Heart: An Evidence-Linked Pipeline for Heart-Failure Feature Engineering
Electronic health record (EHR) feature engineering is a major bottleneck in clinical research and AI, accounting for 39-45% of data scientists' workload. This is especially pronounced in heart failure, which affects an estimated 6.7 million U.S. adults and requires integrating fragmented EHR data with disease-specific, guideline-based clinical reasoning. Existing rule-based and large language model (LLM)-based approaches offer only partial automation with limited maintainability and evidence traceability. We developed the Nimblemind Multi-Agent System (nMAS), an evidence-linked, rubr